Scientists Find "Off Switch" for Alzheimer's Inflammation

Scientists may have found a way to quiet the destructive brain inflammation that fuels Alzheimer's disease.

Researchers at Scripps Research Institute discovered that a protein called STING gets chemically modified in Alzheimer's patients, pushing the brain's immune system into a harmful overdrive state. When they blocked this specific change in mice, inflammation dropped and the connections between brain cells stayed protected.

The breakthrough centers on a chemical reaction called S-nitrosylation that attaches to a specific spot on the STING protein. Once modified, STING forms larger clusters that trigger waves of inflammation instead of the normal, controlled immune response the brain needs.

Lead researcher Stuart Lipton and his team found high levels of this altered protein in brain tissue from people who died with Alzheimer's disease. They saw the same pattern in lab-grown human brain cells and in mice with the condition.

The Ripple Effect

The discovery reveals how inflammation becomes trapped in a vicious cycle. Protein clumps associated with Alzheimer's, combined with aging and environmental exposures like air pollution, spark inflammation that generates nitric oxide. That nitric oxide then modifies STING, which drives even more inflammation and keeps the cycle spinning.

When the research team engineered mice with a version of STING that couldn't be chemically altered, brain immune cells showed much lower inflammation levels. Even more exciting, the synapses connecting nerve cells stayed healthy. Preserving these connections is strongly linked to protecting against cognitive decline in dementia.

What makes this approach particularly promising is its precision. The treatment wouldn't shut down the entire immune system or block STING completely. Instead, it would prevent just the overactivation that causes harm while letting the protein continue its normal protective work against infections.

Lipton's team is now developing small molecules designed to block the specific site where the harmful chemical change occurs. The researchers plan to test these potential treatments in further studies, moving closer to therapies that could help the more than 6 million Americans living with Alzheimer's disease.

After 30 years of studying this chemical process, Lipton is watching his fundamental research translate into hope for patients facing one of medicine's most challenging diseases.